Compositions and methods for modulating apoe
Patent Information
- Application Number
- PCT/US2024/034006
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-21
- Filing Date
- 2024-06-14
- Publication Date
- 2025-04-17
AI Technical Summary
Current treatments for neurodegenerative diseases such as Alzheimer’s and dementia with Lewy Bodies are inadequate in addressing the accumulation of amyloid plaques and neurofibrillary tangles, as existing therapies fail to effectively modulate the key proteins involved in these processes.
The development of isolated nucleic acids, specifically antisense oligonucleotides, that bind to mRNA transcripts of genes like APOE to modulate their expression, reducing the production of apolipoprotein E, thereby decreasing amyloid plaque formation and associated neurodegenerative effects.
This approach effectively decreases the levels of functional apolipoprotein E, leading to reduced amyloid plaque formation and potentially treating or preventing neurodegenerative diseases by targeting the underlying genetic mechanisms.